Vallerie V McLaughlin MD
Adult Congenital Heart Disease
Professor, Internal Medicine, University of Michigan Medical School
Join to View Full Profile
1500 E Medical Center DrAnn Arbor, MI 48109
Phone+1 734-936-4000
Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Cardiovascular Disease, 1992 - 1995
University of MichiganResidency, Internal Medicine, 1989 - 1992- Northwestern University The Feinberg School of MedicineClass of 1989
Certifications & Licensure
MI State Medical License 1991 - 2025
IL State Medical License 1992 - 2005
American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
- Eisenmenger Quality Enhancement Research Initiative Start of enrollment: 2012 Jul 01
- Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients.Franck F Rahaghi, Marc Humbert, Marius M Hoeper, R James White, Robert P Frantz
The Lancet. Respiratory Medicine. 2025-04-01 - Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.Mardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, Ekkehard Grünig, Marius M Hoeper
The Journal of Heart and Lung Transplantation. 2025-04-01 - Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.Marc Humbert, Vallerie V McLaughlin, David B Badesch, H Ardeschir Ghofrani, J Simon R Gibbs
The New England Journal of Medicine. 2025-03-31
Lectures
- Relieving the Pressure of Pulmonary Arterial Hypertension: Key Takeaways for the General Cardiologist Moving from Vague Symptoms to Ensuring Adequate Treatment Response2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Pulmonary Hypertension: From Etiology to Therapy2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Authored Content
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityFebruary 2018
Press Mentions
With Efficacy Assured, Merck Halts Another Trial of Blockbuster-to-Be WinrevairJanuary 30th, 2025- Merck to Stop Trial Evaluating Winrevair Pulmonary Arterial Hypertension EarlyJanuary 30th, 2025
- ZENITH Trial Breakthrough: Winrevair Shows Significant Impact on Outcomes of Pulmonary Arterial HypertensionDecember 4th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
